Carlson et al. did not appreciate any significant change in hormonal parameters including prolactin, testosterone, LH, FSH, TSH, free T4, T3, GH, and IGF-1, before and during EPO therapy in a small cohort of older adults with end-stage renal disease under hemodialysis [239]. This evidence concerns the gene EPO and stage 5 chronic kidney disease.